Eli Lilly chief scientist Daniel M. Skovronsky: Beware elected leaders who would weaken patents

Taking stock of the drug industry, from the lab to the medicine chest

October 17, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Photo illustration: STAT; Photo: Eli Lilly and Co STAT+ | Opinion: Eli Lilly chief scientist Daniel M. Skovronsky: Beware elected leaders who would weaken patents "The current policy environment is increasingly hostile to inventors of new medicines," writes Daniel M. Skovronsky, Eli Lilly's chief scientist. By Daniel M. Skovronsky STAT+ | How invisible medical groups are powering telehealth's GLP-1 'gold rush' Telehealth sites prescribing GLP-1s get off the ground in a matter of days by "renting" the services of these medical groups. By Katie Palmer STAT+ | Alnylam's CEO on welcoming competition, turning a profit, and a 'spine-tingling moment' Yvonne Greenstreet predicts vutrisiran will become multibillion-dollar product for ATTR-cardiomyopathy, despite increasing competition. By Elizabeth Cooney David Goldman/AP STAT+ | Medicare Advantage insurers ramped up use of technology to deny claims, Senate investigation shows The Senate report extensively cites STAT's investigation of the use of algorithms and artificial intelligence within Medicare Advantage plans. By Bob Herman and Casey Ross Biotech veteran Tony Coles on partisan politics and fulfilling a promise to his co-founder Coles has arguably been just as active pushing the drug industry and other business leaders towards difficult conversations as he has been on making deals. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser